To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2008.12.049 | DOI Listing |
Publication Analysis
Top Keywords
chronic henoch-schönlein
12
henoch-schönlein purpura
12
severe refractory
8
refractory chronic
8
rituximab therapy
4
therapy severe
4
purpura report
4
report efficacy
4
efficacy rituximab
4
rituximab rtx
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!